Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCWLHD)

Drug Name

Upifitamab rilsodotin Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Ovarian cancer	2C73	Phase 3	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Sodium/phosphate cotransporter 2B (SLC34A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
XMT-1592	DMU6TG7	Non-small-cell lung cancer	2C25.Y	Phase 1/2	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Sodium/phosphate cotransporter 2B (SLC34A2)	TTQPZTM	NPT2B_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05329545) A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants With Recurrent, Platinum-Sensitive, Ovarian Cancer (UP-NEXT). U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Mersana Therapeutics
3	Clinical pipeline report, company report or official report of Mersana Therapeutics.